1. Park JH, Schuchman EH. Acid ceramidase and human disease. Biochim Biophys Acta 2006; 1758(12): 2133-8.
2. Sands MS. Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology. EMBO Mol Med 2013; 5(6): 799-801.
3. Kyriakie Sarafoglou K, Hoffmann G, Roth K. Pediatric endocrinology and inborn errors of
metabolism. 1st ed. New York, NY: McGraw-Hill Education; 2008. p. 745.
4. Ahmad A, Mazhar A, Anwar M. Farber disease: a rare neurodegenerative disorder. J Coll Physicians Surg Pak 2009; 19(1): 67-8.
5. Zappatini-Tommasi L, Dumontel C, Guibaud P, Girod C. Farber disease: an ultrastructural study. Virchows Archiv A PatholAnat 1992; 420(3): 281-90.
6. Kliegman RM, Stanton B, Geme J, Schor NF. Nelson text book of pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016; p. 714.
7. Moser HW, Linke T, Fensom AH, Levade T, Sandhoff K. Acid ceramidase deficiency: farber lipogranulomatosis. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, et al. editors. The online metabolic and molecular bases of inherited diseases. New York, NY: McGrawHill Inc. 2001. p. 3573-88.
8. Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J 2007; 5: 15.
9. Fernandz J, Sundubrcy JM, van Bergeh G. Inborn metabolic diseases: diagnosis and treatment. 4th ed. New York, NY: Springer-Verlag; 2006.
10. Ehlert K, Frosch M, Fehse N, Zander A, Roth J, Vormoor J. Farber disease: clinical presentation, pathogenesis and a new approach to treatment. Pediatr Rheumatol Online J 2007; 5: 15.